Navigation Links
NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
Date:5/16/2012

NEW ORLEANS, May 16, 2012 /PRNewswire/ -- NuMe Health LLC, a biotechnology company developing evidence-based cobiotic™ products that modify the bacteria that live in the gastrointestinal (GI) tract to support health and well-being, today announced that it has closed a $1.5 million Series A financing.  NuMe also announced that the company is initiating a clinical trial of its lead cobiotic product, NM504, which is being developed for the prediabetic population to support maintenance of healthy blood glucose levels and metabolic fitness.

The Series A financing was led by existing investor BVM Capital with the participation of company insiders, and several new private investors also joined in the round.  The company intends to use the funds to advance NM504 towards commercialization, including developing the initial format for its first consumer product, completing the pilot clinical trial and preparing for an initial direct-to-consumer launch.

"This is an exciting time for NuMe Health as we initiate the first clinical trial of our lead cobiotic product and begin to prepare for commercial launch," said Dean P. Stull, PhD, chief executive officer of NuMe Health.  "We are pleased that our investors appreciate the potential of our revolutionary approach to support healthy blood glucose levels and metabolic fitness, and we are delighted that the trial will be conducted at the Pennington Biomedical Research Center, which has a global reputation for its clinical research in obesity and metabolic diseases."

NM504 contains a proprietary blend of prebiotic and other ingredients formulated to help prediabetic individuals achieve healthy blood glucose levels and manage their body weight by altering the composition of their GI bacteria.  Prediabetes is a condition in which individuals have blood glucose levels higher than normal but not high enough to be classified as diabetes.  According to The Centers for Disease Control and Prevention, people with prediabetes have an increased risk of developing type 2 diabetes, heart disease, and stroke.  NM504 supports the activity of bacteria that inhibit appetite signals and stimulate satiety signals, and it also inhibits bacteria that convert undigested nutrients into extra calories.  In addition, NM504 shifts the bacteria environment of the microbiome to decrease the absorption of sugar and cholesterol. 

"We welcomed the chance to lead the Series A financing due to the opportunity we see for NuMe Health to be a leader in applying the emerging knowledge of the human microbiome to prediabetes and related health conditions," said  Ross P. Barrett, managing partner of BVM Capital and a director of NuMe Health.  "We also want to acknowledge the support from BioDistrict New Orleans, the New Orleans BioInnovation Center, Inc., Tulane University and the broader pro-business policy initiatives of the Louisiana Department of Economic Development, which have been instrumental in helping to close this round."

The NM504 clinical trial is a placebo-controlled, double-blinded, proof-of-concept study that will test the ability of two different doses of NM504 to alter the human microbiome and support healthy insulin sensitivity and fasting blood glucose levels in prediabetic individuals.  It will assess blood biomarkers associated with GI and metabolic health, relevant safety parameters and GI bacterial changes consistent with the expected mechanism of action of NM504.

Cobiotics are combinations of naturally occurring food components that are not digested but that act to control GI bacteria in beneficial ways.  NuMe's initial cobiotic products are derived from bioactive plant ingredients that promote the growth of specific bacteria with the potential to positively affect metabolic conditions.  NuMe's cobiotic products are evidence-based and are being developed using rigorous scientific methods and clinical studies to assess and validate their claims.

About NuMe HealthNuMe Health is a biotechnology company developing and marketing proprietary, evidence-based cobiotic products--combinations of food components designed to maintain health by modifying the bacteria populations that live in the GI tract.  NuMe's first product, NM504, is designed to support healthy blood glucose levels in prediabetic individuals.  Future products will address other conditions involving metabolism and the maintenance of healthy body weight.  For more information, visit www.numehealth.com.Contacts:NuMe Health

MediaDean Stull 

Barbara Lindheimdstull@numehealth.com 

212 584-2276 blindheim@bllbiopartners.com


'/>"/>

SOURCE NuMe Health LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
2. Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
3. IntelligentMDx Announces CE-Marking of a new high-throughput test for Group B Streptococcus intended to improve womens health and prenatal care
4. Cardinal Health Brings Resolution to Litigation with DEA Settlement
5. Cambrex To Present At Jefferies 2012 Global Healthcare Conference
6. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
7. S1 Biopharma Expands Focus to Include Male Sexual Health
8. Viztek Announces Availability of Opal-Mammo Integrated Mammography Suite - Complete Womens Health Package Combines PACS and Tracking Software
9. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
10. Allied Healthcare Products Reports Loss on Sales Decline
11. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...
(Date:12/8/2016)... Dec. 8, 2016 True Health Diagnostics ... leading-edge laboratory services and management expertise to hospital ... , allowing more doctors and patients to benefit ... solutions. Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... systems, under pressure to contain costs, have struggled ...
(Date:12/8/2016)... NORWALK, Connecticut , 8. Dezember 2016 Mederi Therapeutics Inc ... Stretta-Therapie – eine nicht-operative Behandlungsmethode für gastroösophageale Refluxerkrankung (GERD) – in ... Reading ... Live ... by Professor Jun Liu, Director of Endoscopy at Wuhan Union Hospital ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... California Senate Bill (SB) 863, signed into law in 2012, ... and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , a ... study, medical payments per claim in California decreased 4 percent in 2013 and then ...
(Date:12/8/2016)... San Francisco, California (PRWEB) , ... December 08, 2016 , ... ... health coaches, has raised an $18M Series B led by Canvas Ventures . ... use the capital to scale its mobile platform to serve more consumers who are ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Jefferson County, is announcing the launch of a ... Birmingham. , The number of homeless women and children in Birmingham has grown ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Compretta Insurance Agency, a family ... in and around the Hancock County area, is announcing the launch of a charity ... , The Hancock County Food Pantry has worked for more than 30 years to ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication to ... of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of ... both sides of the Atlantic with a mechanism to comply with EU data protection ...
Breaking Medicine News(10 mins):